# Cardiol Therapeutics Inc.: overview CRDL · Nasdaq · CIK 1702123 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/crdl.md) · [Financials](/companies/crdl/financials.md) · [Filings](/companies/crdl/filings.md) · [Insiders](/companies/crdl/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.1](/filings/0001104659-24-041952.md) | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(49091.9%)](/filings/0001104659-24-041952.md) | not reported | not reported | not reported | not reported | | Net margin | % | [(40170.4%)](/filings/0001104659-24-041952.md) | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.73)](/filings/0001104659-24-041952.md) | [(0.49)](/filings/0001104659-24-041952.md) | [(0.44)](/filings/0001410578-25-000588.md) | [(0.51)](/filings/0001104659-26-037844.md) | [(0.39)](/filings/0001104659-26-037844.md) | | Free cash flow | $m | [(23.6)](/filings/0001104659-24-041952.md) | [(27.3)](/filings/0001104659-24-041952.md) | [(25.2)](/filings/0001410578-25-000588.md) | [(25.1)](/filings/0001104659-26-037844.md) | [(23.9)](/filings/0001104659-26-037844.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss; Revenue: ifrs-full:Revenue. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/crdl/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MMCAP International Inc. SPC](/funds/1304857.md) | 2026-06-30 | $16.5m | 15,598,560 | | Added +246,243 | | [Tejara Capital Ltd](/funds/1879713.md) | 2026-06-30 | $5.4m | 5,113,822 | | Reduced −16,300 | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $3.5m | 3,325,000 | | Added +600,000 | | [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $1.0m | 975,721 | | Added +180,840 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $844.3k | 796,529 | | Reduced −23,375 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $819.2k | 772,837 | | Added +543,031 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $791.8k | 746,937 | | Added +212,726 | | [INTEGRITY ALLIANCE, LLC.](/funds/1352260.md) | 2026-06-30 | $411.8k | 388,492 | | Reduced −76,533 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $376.3k | 355,030 | | Added +104,609 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $353.9k | 333,900 | | Added +1,500 | ## Recent filings [All 185 filings](/companies/crdl/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-23 | 06:38 ET | [6-K](/filings/0001279569-26-000905.md) | Report of a foreign private issuer, period 2026-09-23 | 0001279569-26-000905 | | 2026-09-16 | 07:36 ET | [6-K](/filings/0001279569-26-000889.md) | Report of a foreign private issuer, period 2026-09-16 | 0001279569-26-000889 | | 2026-09-15 | 19:09 ET | [6-K](/filings/0001104659-26-107594.md) | Report of a foreign private issuer, period 2026-09-14 | 0001104659-26-107594 | | 2026-09-11 | 21:41 ET | [6-K](/filings/0001104659-26-106836.md) | Report of a foreign private issuer, period 2026-09-10 | 0001104659-26-106836 | | 2026-09-10 | 17:11 ET | [6-K](/filings/0001279569-26-000875.md) | Report of a foreign private issuer, period 2026-09-10 | 0001279569-26-000875 | | 2026-09-09 | 08:10 ET | [6-K](/filings/0001279569-26-000867.md) | Report of a foreign private issuer, period 2026-09-09 | 0001279569-26-000867 | | 2026-08-12 | 16:14 ET | [6-K](/filings/0001104659-26-094885.md) | Report of a foreign private issuer, period 2026-06-30 | 0001104659-26-094885 | | 2026-08-05 | 07:38 ET | [6-K](/filings/0001279569-26-000745.md) | Report of a foreign private issuer, period 2026-08-05 | 0001279569-26-000745 | | 2026-07-14 | 07:37 ET | [6-K](/filings/0001279569-26-000670.md) | Report of a foreign private issuer, period 2026-07-14 | 0001279569-26-000670 | | 2026-07-09 | 07:52 ET | [6-K](/filings/0001279569-26-000651.md) | Report of a foreign private issuer, period 2026-07-09 | 0001279569-26-000651 | ## Latest annual report [Form 40-F for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-037844.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1702123 - Tickers: CRDL - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: A6 - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.